Autonomic Nervous System

Heart Attack & Stroke Risks

Diabetes & ANS/HRV

Our Autonomic Nervous System (ANS) and Heart Rate Variability (HRV) device is an FDA-approved Class II medical device used to assess arterial hardening, circulation, heart rate variability, and autonomic nervous system function. 

A low-cost, point-of-care test that can be conducted by a medical assistant.

Identify Heart Attack and Stroke Risks

Diabetic Cardiomyopathy is a disorder of the heart muscle in people with diabetes. Patients with diabetes Type 2 have up to a 74% increased risk of developing Heart Failure, and diabetic patients with HF are four times more likely to die than those without Heart Failure. Importantly, unrecognized HF is highly prevalent in Type 2 diabetics, with over one quarter (27.7%) of those over 60's having previously undiagnosed Heart Failure (HF) in one report. It can lead to the inability of the heart to circulate blood through the body effectively, a state known as heart failure, with an accumulation of fluid in the lungs (pulmonary edema) or legs (peripheral edema). Therefore it is one, if not the, most important assessment to be measured for all Type 2 diabetic patients and people with 2 or more comorbidities. 

The Framingham Study Found that Individuals with Asymptomatic Left Ventricular Systolic Dysfunction (LVSD) at Entry had a Nearly 5-fold Increase in the Risk of Developing Symptomatic HF Compared to those with Normal Left Ventrical Function.

Kannel WB, Gordon T, and National Heart Institute (U.S.) (1968) The Framingham study: An epidemiological investigation of cardiovascular disease. Bethesda, MD., United States. Department of Health, Education, and Welfare, National Institutes of Health.

Heart disease may go undiagnosed until symptoms of myocardial infarction, heart failure, or arrhythmia appear. The goal should be to prevent heart failure symptoms by screening at-risk patients for asymptomatic heart dysfunction and implementing cost-effective interventions in the early stages. Echo is the most common way to diagnose heart failure, but our ANS/HRV can provide an inexpensive early screening for all at-risk patients with a high reimbursement. Also, the cardiorenal axis is a new target for intervention in heart failure. Cardiorenal and metabolic comorbidities are common in most people with diabetes and obesity and the interdependent relationship between the heart and the kidneys is an increasingly important target for intervention in the treatment of heart failure, as addressing both organs together can lead to better outcomes for patients.

Our ANS/HRV test is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). The ANS/HRV can graph the heartbeat as it moves through systolic and diastolic cycles. It tracks deviations in fingertip pressure caused by flexible arteries and produces a tight, regular graph for stiff arteries. Using a proprietary algorithm, the device analyses arterial pulse wave variations and compares them against a large body of research to accurately assess arterial hardening. 

Arterial Health Score: The 1-7 scoring system is highly accurate in assessing arterial hardening, and the final report can reveal early signs of congestive heart failure or heart weakening. This test is critical in detecting arterial hardening or heart weakening well before the patient experiences symptoms. It is especially crucial for diabetic patients and those with high blood pressure or elevated lipids.

Autonomic Balance Test: Our assessment includes an accurate heart rate variability test and autonomic nervous system analysis. It shows if the person is overstressed with a dominant sympathetic nervous system, or fatigued with a suppressed sympathetic and dominant parasympathetic system. It also assigns a stress score and measures the patient's ability to manage stress levels.

COVID-19 Survivors, Regardless of Infection Severity, are More Likely to Develop Cardiovascular Conditions Such as Heart Failure or Coronary Disease within 30 Days Post-Infection.

Long-Term Treatment: For long-term, longer-lasting treatments, you can see changes within 4-6 weeks of starting treatment.

Short-Term Treatments: Some fast-acting treatments (such as some fast absorption nitrous oxide products) can show changes within 10 or 20 minutes.

RECOMMENDATION: It is crucial to create a low-cost, point-of-care test that can be conducted by a minimally trained medical assistant to aid in disease diagnosis, given the challenges faced by primary care providers.

Features of the tests:

Simply Better